This Synthetic Biology Stock Is Soaring, But Investors Shouldn't Overlook A Key Risk

On the surface, it appears that synthetic biology pioneer Amyris (NASDAQ: AMRS) has finally turned a corner. Shares have gained 200% in the last year and are up more than 75% in 2018 on the heels of strong revenue growth in each of the last several quarters. The company sold its high-cost manufacturing facility to the world's leading industrial biotech powerhouse DSM and is now reaping the rewards of a business model built on royalty revenue from the deep-pocketed partner.

Topics:  amyris nasdaq   amrs    amyris   investors   overlook   synthetic biology   revenue   rule   company   business   growth   continue   accounting   

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News